ReviewVox sanguinis2013
Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks.
Review in Vox sanguinis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 95 citations in OpenAlex.
- Trial
- Donor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion.The Journal of clinical investigation · 2020Trial
- Molecular Analysis of Glucose-6-Phosphate Dehydrogenase Gene Mutations in Bangladeshi Individuals.PloS one · 2016Trial
- Glucose-6-Phosphate Dehydrogenase Deficiency Reprograms Macrophage Metabolism in Hyperlipidemia.Blood red cells & iron · 2026Article
- Article
- Evaluation of the impact of malaria and erythrocyte G6PD deficiency on anaemia outcomes among children in Jos Northcentral Nigeria.BMC research notes · 2026Article
- GPX4 regulates lipid peroxidation and ferroptosis of stored red blood cells.Blood red cells & iron · 2025Article
- Red blood cell metabolism: a window on systems health towards clinical metabolomics.Current opinion in hematology · 2025Review
- Hemoglobin Variants as Targets for Stabilizing Drugs.Molecules (Basel, Switzerland) · 2025Review
- Henna-Induced Intravascular Hemolysis in a Glucose-6-Phosphate Dehydrogenase-Deficient Ghanaian Female Child with Full Defect.International medical case reports journal · 2025Article
- Acute hemolytic crisis complicated with ischemic cardiac injury and methemoglobinaemia following ingestion of naphthalene: a case report.Journal of medical case reports · 2024Article
- Rate of glucose-6-phosphate dehydrogenase deficiency in neonatal indirect hyperbilirubinemia at a private tertiary centre.Saudi medical journal · 2024Article
- The Role of Ergothioneine in Red Blood Cell Biology: A Review and Perspective.Antioxidants (Basel, Switzerland) · 2024Review
- Article
- Retinopathy of Prematurity and Glucose-6-Phosphate Dehydrogenase Activity: A Case-Control Study.Indian journal of pediatrics · 2023Article
- The role of chromium supplementation in cardiovascular risk factors: A comprehensive reviews of putative molecular mechanisms.Heliyon · 2023Review
- Chemoprevention of bilirubin encephalopathy with a nanoceutical agent.Pediatric research · 2023Article
- Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia.Malaria journal · 2022Article
- Red cell proteasome modulation by storage, redox metabolism and transfusion.Blood transfusion = Trasfusione del sangue · 2022Article
- Donor sex, age and ethnicity impact stored red blood cell antioxidant metabolism through mechanisms in part explained by glucose 6-phosphate dehydrogenase levels and activity.Haematologica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The hallmark of glucose-6-phosphate dehydrogenase (G6PD) deficiency is red blood cell (RBC) destruction in response to oxidative stress. Patients requiring RBC transfusions may simultaneously receive oxidative medications or have concurrent infections, both of which can induce haemolysis in G6PD-deficient RBCs. Although it is not routine practice to screen healthy blood donors for G6PD deficiency, case reports identified transfusion of G6PD-deficient RBCs as causing haemolysis and other adverse events. In addition, some patient populations may be more at risk for complications associated with transfusions of G6PD-deficient RBCs because they receive RBCs from donors who are more likely to have G6PD deficiency. This review discusses G6PD deficiency, its importance in transfusion medicine, changes in the RBC antioxidant system (of which G6PD is essential) during refrigerated storage and mechanisms of haemolysis. In addition, as yet unanswered questions that could be addressed by translational and clinical studies are identified and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.